Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.53 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | AGXT | P21549 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29585400 | 1.00 | TAAR1 (0.66) | TAAR1CHRM2PNMTNOS1PRMT6 | |
| SCHEMBL1697126 | 0.84 | MAPT (0.64) | TAAR1NOS1PRMT6CYP3A4KDM4E | |
| SCHEMBL19069756 | 0.83 | TAAR1 (0.56) | TAAR1CHRM2PNMTPRMT6CARM1 | |
| SCHEMBL7066938 | 0.82 | CHRM2 (0.74) | TAAR1CHRM2PNMTCYP3A4IDO1 | |
| Hydrochloric Acid SCHEMBL3273205 | 0.81 | MAPT (0.68) | NOS1PRMT6CYP3A4KDM4EMAPT | |
| SCHEMBL30656906 | 0.80 | CHRM2 (0.60) | TAAR1CHRM2PNMTCYP3A4IDO1 | |
| SCHEMBL27908406 | 0.80 | CHRM2 (0.60) | TAAR1CHRM2PNMTCYP3A4IDO1 | |
| SCHEMBL29868670 | 0.79 | CHRM2 (0.65) | TAAR1CHRM2PNMTCYP3A4CYP1A2 | |
| SCHEMBL1108512 | 0.79 | TAAR1 (1.00) | TAAR1CHRM2PNMTPRMT6CARM1 | |
| SCHEMBL3514622 | 0.79 | CHRM2 (0.65) | TAAR1CHRM2PNMTCYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118878-A | Paeonol carbamate compound, pharmaceutical preparation, preparation method and application | 安徽省第二人民医院(安徽医学高等专科学校附属医院、安徽省职业病防治院) | 2024-12-13 | — | — | CN | claimed |
| CN-116283769-A | Cyclobutane-pyridine sulfonamide compound | 绍兴市上虞区武汉理工大学高等研究院 | 2023-06-23 | — | — | CN | claimed |
| CN-112279786-A | Cannabidiol carbamate compound, pharmaceutical preparation, preparation method and application | 汤文建 | 2021-01-29 | — | — | CN | claimed |
| CN-1832928-B | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2012-07-04 | — | — | CN | claimed |
| JP-4838121-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1641764-B1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| EP-2298743-A1 | 5-membered heterocycle-based P38 kinase inhibitors | Novartis AG (CH) | 2011-03-23 | — | — | EP | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| CN-101410366-A | Substituted bicyclic ring derivatives and uses thereof | ASAHI KASEI PHARMA CORP (JP) | 2009-04-15 | — | — | CN | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | claimed |
| JP-2007521278-A | — | — | 2007-08-02 | — | — | JP | claimed |
| CN-1832928-A | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2006-09-13 | — | — | CN | claimed |
| EP-1641764-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | Novartis AG (CH) | 2006-04-05 | — | — | EP | claimed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2005-03-03 | — | — | US | claimed |
| WO-2005009973-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-03 | — | — | WO | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | TAAR1 1127/4885CHRM2 553/4885PNMT 3102/4885 |
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | TAAR1 2016/4885CHRM2 4584/4885PNMT 4261/4885 |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | TAAR1 3251/4885CHRM2 3164/4885PNMT 3898/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | TAAR1 104/4885CHRM2 1185/4885PNMT 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.